NanoViricides Inc (NNVC) 옵션

NNVC..................https://stockcharts.com/h-sc/ui?s=NNVC&p=W&b=5&g=0&id=p86431144783

I’m not sure why, but I can’t believe you are still a believer. Now, more than ever, you have to admit I was right all along. Or couldn’t you care less?

Or more broadly:
https://clinicaltrials.gov/search?term=nanoviricides

EVER.

https://clinicaltrials.gov/search?intr=NV-387

Filed Friday: https://www.sec.gov/Archives/edgar/data/1379006/000205258725000002/0002052587-25-000002-index.htm

Uncle Miltie has assigned Powers of Attorney and says he is no longer a 10% owner.

Another clear-as-mud Diwan PR.Agreed

The badmouthing of the SIGA drug doesn't seem to be entirely justified.
https://en.wikipedia.org/wiki/SIGA_Technologies

However there does seem to be some justification for your question mark:
"So - it appears that they plan to target monkeypox for a Phase II?"

Another clear-as-mud Diwan PR.

NanoViricides Engages CRO for Phase II Clinical Trial - Odd though that the press release here doesn't mention any CRO by name.

So - it appears that they plan to target monkeypox for a Phase II?

https://finance.yahoo.com/news/nanoviricides-engages-cro-phase-ii-113000925.html

SHELTON, CT / ACCESS Newswire / January 27, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum antiviral drug NV-387 further into the regulatory pipeline.

"NV-387, our broad-spectrum antiviral drug is poised to cause a revolution in treatment of viral diseases, just as antibiotics revolutionized the treatment of bacterial diseases," said Anil R. Diwan, Ph.D., further commenting, "Our regulatory development strategy for this drug is now further advancing into a Phase II clinical trial stage."

The Company has previously stated that it is working towards a Phase II clinical trial to evaluate the effectiveness of NV-387 for the treatment of MPox patients. MPox disease, caused by the human Mpox virus (hMPXV) has been causing a regional pandemic encompassing several countries in the African region, including the Democratic Republic of Congo (DRC), Uganda, and others. It led to the WHO declaring a Public Health Emergency of International Concern ("PHEIC") on August 14, 2024.

There is no drug available for the treatment of hMPXV infection that causes the MPox disease. A clinical trial of tecovirimat (TPOXX®, SIGA) failed to demonstrate any effectiveness over placebo, as per a NIH press release on August 15, 2024.

In July 2024, SIGA received a procurement order for $112.5 million of oral TPOXX from the U.S. Government under the 19C BARDA contract, for delivery to the U.S. Strategic National Stockpile (SNS), despite the clinical trial failure. Additionally, in August, 2024, SIGA received a procurement contract and related order from the U.S. Department of Defense for approximately $9 million of oral TPOXX, as well as a small amount of IV TPOXX, despite clinical trial failure.

"These desperate attempts by the Previous US Administration to acquire an ineffective drug with hundreds of millions of dollars of taxpayer money only go to show how sorely a truly effective antiviral drug that works against MPox/Smallpox is needed by the government agencies," commented Anil R. Diwan, PhD, President and Executive Chairman of the Company.

NV-387 was found to possess strong antiviral activity against an orthopoxvirus in an animal model that is considered an important model to establish potential effectiveness against MPox and Smallpox viruses, as all of these viruses belong to the same family of orthopoxviruses.

In fact, NV-387 effectiveness matched the effectiveness of the small chemical drug tecovirimat in two different models of infection, one was direct skin infection, and the other was a direct lung infection, by the virus.

Escape of virus from tecovirimat can occur by a single point mutation in a viral protein called VP-37.

In contrast, viruses are highly unlikely to escape NV-387 because no matter how much the virus changes in the field, it continues to use sulfated proteoglycans such as HSPG as "attachment receptor" in order to cause cell infection. NV-387 mimics the sulfated proteoglycan signature feature that the viruses require.

NV-387 is host-mimetic drug that "looks like a cell" to the virus, displaying numerous ligands that mimic the sulfated proteoglycan, enticing the virus to bind to and become engulfed by the NV-387 dynamic shape-shifting polymeric micelle.

Vaccines, antibodies, and small chemical drugs such as tecovirimat for MPox/Smallpox, or oseltamivir (Tamiflu®), baloxavir (Xofluza®) for Influenza are readily escaped by viruses wirth small changes that viruses undergo as they are faced with these challenges in the field.

Therefore development of NV-387, a broad-spectrum host-mimetic, direct-acting antiviral drug that the viruses cannot escape even as they change constantly, will be revolutionary once the drug undergoes regulatory development for approval for use in humans.

NV-387 has already been found to be able to cure lethally RSV infected mice.

NV-387 was found to be significantly superior to oseltamivir (Tamiflu®), baloxavir (Xofluza®), and premivir (Rapivab®) in a lethal Influenza lung infection model designed to rank-order the effectiveness of these various drugs.

New viruses and existing viruses acquiring greater pathology and infectivity are bound to keep appearing in time. To combat such threats, we need to develop broad-spectrum drug arsenal that the viruses cannot escape. Vaccines and antibodies simply will not do, as their limitations have become clearly evident during the COVID-19 pandemic.

About NanoViricides

NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.


This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.


The phrases "safety", "effectiveness" and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

Where stated with an ® , the name is a registered trademark, which belongs to the owner of the trademark name.

FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for "Active Pharmaceutical Ingredient". WHO is the World Health Organization. R&D refers to Research and Development.

Contact:

NanoViricides, Inc., info@nanoviricides.com
Public Relations Contact: ir@nanoviricides.com

SOURCE: NanoViricides, Inc.

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025
6:31 AM ET 1/13/25 | Dow Jones
SHELTON, CT / ACCESSWIRE / January 13, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced today that it is presenting at Biotech Showcase(TM) 2025 in San Fransisco, being held in parallel to the JP Morgan Life Sciences Conference.

Oh Boy!!!!! Another meeting/conference???!!

So - Hey - Diwan - when is a new trial going to get going?

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

https://markets.businessinsider.com/news/stocks/nanoviricides-is-in-a-great-position-to-fight-potential-bird-flu-pandemic-with-a-drug-that-the-mercurial-h5n1-influenza-a-virus-is-unlikely-to-escape-1034166815

Nothing particularly new or novel in this PR - Just allusions to two different Phase II type trials. Monkey Pox in Africa and "respiratory virus infections". No indication though as to when they might start, or how NNVC plans to pay for the trial expenses.

me

Nanoviricides means Kill virus particles. ( this is what the word cide means! KILL or CURE) and *Nano is for small virus cells.)

There is a WAR within our human body when we get infected with a virus! The war starts when the virus is somehow transmitted to our system. Our body is prepared to fight all types of viruses. And we need to win the war or else!
There are an estimated 10 nonillion individual viruses on our planet, which is enough to assign one to every star in the universe 100 million times over1. Each day, more than 700 million viruses, mainly of marine origin, are deposited from Earth’s atmosphere onto every square meter of our planet’s surface2. However, only about 9,110 named species of viruses are currently listed3. (internet)
In my mind I am looking at two armies in the HUMAN battlefield. The virus is looking for a host to invade and then replicate within and explode the cell (or leak out) when its offspring and mutations overflow the captured cell. There are millions of cloned cells and mutations that emanate from one captured host cell, each seeking to replicate its ancestor's actions. So it can take only one virus cell to continue the war. The virus can also duplicate itself in the bloodstream beginning or keeping its sickness active. This singular description is actually replicated hundreds of millions of times until every virus particle is killed and you are "CURED". Only when all the cells are eliminated can this be declared a WIN FOR THE BODY. The body can sometimes win slowly (or not), (my mom's Shingles lasted 9 months. but mine only 2 months). Without Nanoviricides' suicidal tanks cruising through the bloodstream the time to CURE is variable, if your body can cure itself

This company has expanded, and then contracted it's 'clinical research pipeline' for far too many years now.

Down again, I see.

Whatever NNVC is paying its social media pimps, it’s too much.

$NNVC's future looks bright as it expands its clinical research pipeline.
https://tinyurl.com/ya5zfmm9

In the future NNVC will be just another insider enrichment penny stock scam that gets delisted. After all, the CEO has form in that respect.

In the future, $NNVC could be the gold standard in virology.

https://profiles.smallcapsdaily.com/nnvc/

What bullshit. It’s down again.

NNVC needs new pimps - the current ones are pathetic.

Momentum grows for $NNVC—it’s trending across industries!
https://tinyurl.com/ye28duaz

"Good news has given $NNVC a boost"

What good news is that then? And where's this boost of which you speak?

I suspect that NNVC will eventually realise that paying penny stock pimps to tout their stock is a little like urinating in your trousers - it gives you a nice warm feeling at the time, but you soon come to regret it.

Good news has given $NNVC a boost, and the bullish sentiment on the charts is exciting.

Expect this stock to capitalize on emerging trends in the market!
https://tinyurl.com/kf7cb3e4

I wonder why NNVC has hired the dregs of the penny stock pimping business to tout its shares instead of focussing on R&D?

Maybe they’re not an R&D company after all, but just a share selling scam.

$NNVC is trending upward! Poised for a bullish run, this stock is a must-watch for impressive growth potential.

🚀 $NNVC is flying high—be part of this exciting upward trend!

In case you hadn’t noticed, NNVC’s price trajectory is downwards, both short term and long term.

That’s because it’s primarily a share selling operation, disguised as a would-be biotech start up.

$NNVC’s strong price action reflects its upward trajectory—exciting days ahead!
https://tinyurl.com/2ph6umwn

$NNVC’s antiviral approach has the potential to change the healthcare landscape forever.

$NNVC is making strides with rising prices and high trading volume.

💥 Attention! $NNVC is leading the way in revolutionary viral defense!

https://www.nanoviricides.com/

$NNVC’s bullish momentum is clear with its rising price and increasing market cap.

That explains the recent burst of activity here.

But I wonder why NNVC spends money on penny stock pimps when it's supposed to be a biotech R&D company?

Make it make sense, somebody.

Nonsense. Bought and paid for nonsense:
"SCD Media LLC (d/b/a “Smallcaps Daily”), hereinafter referred to as “Smallcaps Daily,” and their affiliates and control persons (the “Publisher”) are in the business of publishing favorable information and/or advertisements (the “Information”) about the securities of publicly traded companies (each an “Issuer” or collectively the “Issuers”) in exchange for compensation (the “Campaigns”)."
https://profiles.smallcapsdaily.com/nnvc/

$NNVC plans Phase II trials for MPox in Central Africa and RSV in the USA. Addressing urgent global health crises.
Know more: https://tinyurl.com/58b8wyjc

$NNVC is moving upward! Strong momentum points to potential gains.
http://tiny.cc/km9xzz

A real humdinger:
https://ih.advfn.com/stock-market/AMEX/nanoviricides-NNVC/chart/streaming

$NNVC continues to rise—an opportunity you can’t ignore!

https://www.nanoviricides.com/

"$NNVC is gaining momentum—watch closely for exciting market moves! 📈"

Click on the 3 month chart on the right. It looks like the little thing that you posted only yours is upside down.
Momentum my ass.

💥 Investors are watching $NNVC—strong growth is right around the corner! 🚀



https://www.nanoviricides.com/

💥 Investors are watching $NNVC—strong growth is right around the corner! 🚀

🔥 $NNVC is ready for big moves!

$NNVC is gaining momentum—watch closely for exciting market moves! 📈

$NNVC is looking strong! Bullish indicators are lighting up, and performance is on point.
Know more: https://tinyurl.com/mrxbeh58

$NNVC gains 2.81%, now $1.3776—progress fueling excitement!
https://iotracker96.com/Ry2vp

Bring back Uncle Miltie and Gene Gene the Lyin' Machine. Burns and Allen seem to be out of material.

"The phrases "safety", "effectiveness" and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. "
He had to be forced to acknowledge abusing those terms. Ironically he's doing so in a PR in which he doesn't lay claim to his creations possessing either quality.

Oh Boy!!!! Another Conference!!!

How about an update on how a Phase II trial is getting funded and what the actual 'disease' target is going to be?

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
12:02 AM ET 11/4/24 | Dow Jones

SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's President and Executive Chairman, will be presenting a corporate update at the Spartan Capital Investors Conference on Monday, November 4, 2024 (today) at 9:45 am. The Conference will be held at the Pierre Hotel in New York City.

Event The Spartan Capital Investors Conference
2024
Day & Date Monday, November 4, 2024
----------------------------------------
Location The Pierre Hotel, New York, NY, USA.
----------------------------------------
Talk Title Revolutionizing Antiviral Treatments,
Phase 2-Ready, Broad-Spectrum Lead Drug
NV-387 Addresses a $2.5 to $4.3 Billion
Market for RSV Alone
----------------------------------------
Presenter Anil R. Diwan, PhD, President & Exec.
Chairman, NanoViricides, Inc.
----------------------------------------
Track Collition Room
----------------------------------------
Time 09:45 to 10:00
----------------------------------------

Dr. Diwan will discuss the revolutionary broad-spectrum antiviral drug candidate NV-387, that is enabled by the nanoviricides technology platform. NV-387 has successfully completed Phase I clinical trial.

NV-387 has shown strong antiviral activity, with substantial superiority to existing drugs, against a number of viral diseases in animal models. These include Influenza, RSV, COVID, Influenza, and MPox/Smallpox related animal models.

The overall market size for these indications is anticipated to be more than $10 Billion by 2027.

About Spartan Capital Investor Conference 2024

The conference, organized in partnership with B2i Digital, a leading digital marketing firm specializing in investor communications, will feature presentations from over 30 carefully selected companies. The event will include panel discussions, one-on-one meetings, and networking sessions to maximize interactions between investors and presenters.

For more information about the conference and registration details, please visit Spartan Capital's conference page.

About NanoViricides

NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide(TM) class of drug candidates and the nanoviricide(TM) technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour(R) nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases "safety", "effectiveness" and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for "Active Pharmaceutical Ingredient". WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.

info@nanoviricides.com
Public Relations Contact:
ir@nanoviricides.com
SOURCE: NanoViricides, Inc.
View the original press release on accesswire.com

Yep - Diwan set up Karveer - He's skirting around the edges of what he 'has' to tell investors by not mentioning that issue. NNVC/Theracor/Karveer are an inbred set of things.

https://www.sec.gov/Archives/edgar/data/1379006/000110465924108620/tm2426151d1_def14a.htm
The Proxy Statement is a very comprehensive document. NNVC's mentions Diwan 73 times and Karveer an even dozen yet there is no mention of Diwan's relationship with Karveer and we know that he has one.


About Karveer Meditech Private Limited

Karveer Meditech Private Limited is a small and aspiring dynamic pharmaceutical company in India. It has developed and commercialized in local markets more than a dozen different generic and semi-branded pharmaceutical drugs as well as Ayurvedic medicines and vitaminized nutritional supplement protein powder products. It was co-founded by Dr. Anil Diwan, who serves as a Director and is a passive investor. Dr. Diwan is also co-founder of and President and Executive Chairman of the Board of NanoViricides. Karveer Meditech is independently managed by its Managing Director in India.
https://www.biospace.com/nanoviricides-has-shipped-drug-products-for-impending-clinical-trials-of-nv-cov-2-its-covid-drug-candidate

Yet another hype PR/Podcast from Anil.

https://theconferenceforum.org/pharmatalkradio/antiviral-drug-development-how-nanoviricides-is-overcoming-challenges-to-the-current-model

The beating of the PR drum continues - but - when will we find out when/if NNVC gets an actual Phase II trial started, what specific illness and virus are they planning on taking on, and how they intend to actually fund the work?

NNVC..................................https://stockcharts.com/h-sc/ui?s=NNVC&p=W&b=5&g=0&id=p86431144783